Compare FLUX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | NRSN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 14.2M |
| IPO Year | 2019 | 2021 |
| Metric | FLUX | NRSN |
|---|---|---|
| Price | $0.63 | $0.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 431.0K | 257.9K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $0.47 | $0.25 |
| 52 Week High | $7.55 | $1.30 |
| Indicator | FLUX | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 42.78 |
| Support Level | $0.51 | $0.39 |
| Resistance Level | $0.85 | $0.74 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 33.28 | 72.28 |
Flux Power Holdings Inc. designs, develops, manufactures, and sells a portfolio of lithium-ion energy storage solutions for the electrification of a range of industrial and commercial sectors, which include material handling, airport ground support equipment (GSE), and stationary energy storage. It offers a high-power battery cell management system(BMS). The BMS serves as the brain of the energy storage solution, managing cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company's product portfolio includes Battery Technology and Energy Management solutions.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.